5-Amino-1MQ

5-Amino-1MQ is a small molecule that blocks an enzyme called NNMT, and it is increasingly sold online as a “fat-loss peptide.” It is not a peptide, and that wrong label is the first warning sign. The underlying biology is genuinely interesting and the mouse results look promising, but the honest summary is simple: as of mid-2026 there is no verifiable human trial, no approval, and every believable result for whether it works comes from animals or cells in a dish. This profile sorts the real early-stage science from the grey-market sales pitch.

What it is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, cell-permeable (able to pass into cells) blocker of an enzyme called nicotinamide N-methyltransferase, or NNMT. Chemically it is a methylquinolinium compound, usually sold as the iodide salt. It is NOT a peptide, and not a SARM or anabolic steroid. It is a different thing from its parent compound, 1-methylquinolinium (1-MQ). Adding the 5-amino piece makes it roughly ten times more potent — its IC50 (the concentration needed to block half the enzyme’s activity; lower means stronger) is about 1.2 µM, versus about 12 µM for 1-MQ. That figure is confirmed in the NNMT mechanism review (Iyamu & Huang 2021).

Here is how it works. Normally, the NNMT enzyme attaches a methyl group (a small chemical tag) to a molecule called nicotinamide, turning it into 1-methylnicotinamide (1-MNA). To do that, it uses up S-adenosylmethionine (SAM), the body’s main methyl-tag donor. 5-Amino-1MQ slots into the same pocket where nicotinamide would normally sit — so it competes with nicotinamide for that spot, rather than working through some vague general mechanism. By shutting NNMT down, it is thought to save SAM (the methyl-donor supply) and push nicotinamide back toward making NAD+ (a key energy-carrying molecule), with knock-on effects on how fat cells handle energy. Because NNMT is present in unusually high amounts in fat tissue and the liver in obesity, the enzyme makes a tempting target for treating metabolic disease — and that is the whole reason this compound exists.

One important catch about how clean its action is: the original paper called these methylquinolinium blockers selective (meaning they hit NNMT and little else). But the 2021 mechanism review specifically warns that this family of chemicals has limited selectivity and low metabolic stability (it breaks down quickly in the body). So treat “highly selective” as a hopeful claim, not a settled fact.

The claims

Sellers and clinics market 5-amino-1MQ for fat loss and weight reduction, “boosting NAD+,” better insulin sensitivity and metabolic health, and — more and more — “muscle preservation,” with the pitch that you drop fat without losing lean muscle. Some pages also claim that early human (Phase 1) trials have been “registered in some geographies.” It is widely sold as a “research chemical” or grey-market capsule, and very often mislabeled as a peptide.

What the evidence actually shows

Human evidence: none you can verify. No published human trial of whether it works or is safe could be confirmed in the peer-reviewed literature, and no genuine ClinicalTrials.gov listing (Phase 1, 2, or 3) could be verified. Seller claims of “registered Phase 1 trials” come with no verifiable registry ID number — so treat that as unconfirmed and flimsy. Any human benefit for weight, muscle, or metabolism is unproven.

Animal and early-stage research (the actual evidence base):

• The founding discovery — small-molecule NNMT blockers (the methylquinolinium group, including 5-amino-1MQ) reversed high-fat-diet obesity in mice: lower body weight, less white fat, smaller fat cells, and lower blood cholesterol; reported as selective. Animal only. (Neelakantan et al., Biochemical Pharmacology 2018.)
• Metabolic disease model — “5A1MQ” produced dose-dependent reductions in body-weight and fat-mass gain (more drug, bigger effect), improved how well mice cleared sugar (oral glucose tolerance) and their insulin sensitivity, and reduced hepatic steatosis (fat buildup in the liver) in obese mice fed a high-fat diet. Animal only. (Babula et al., Diabetes, Obesity and Metabolism 2024.)
• Diet + NNMT blocking / gut bacteria — blocking NNMT (5-amino-1MQ) alongside a reduced-calorie, low-fat diet produced a distinctive mix of gut bacteria (the cecal microbiome) in obese mice. Animal only. (Dimet-Wiley et al., Scientific Reports 2022.)
• Muscle and aging — in aged (22-month-old) female mice, blocking NNMT increased grip strength (about 40% in inactive mice, about 60% when paired with exercise, with the two effects adding together) and improved running and muscle function. Animal only. (Dimet-Wiley et al., Scientific Reports 2024.)
• Wider class context — a different NNMT blocker, JBSNF-000088 (not 5-amino-1MQ), reduced weight in obese mice on a high-fat diet (Kannt et al., Scientific Reports 2018). Useful as proof that the general approach can work, but it is not the same compound.

A word on the “muscle preservation” / “lose fat, keep lean mass” pitch: it is partly backed by the aged-mouse muscle data, but it was not directly shown as preserved lean mass in the obesity studies — those measured fat tissue and fat-cell size, not whether lean mass was protected. So treat the lean-sparing claim as suggestive, not established.

Legal and regulatory status

• FDA: Preclinical/research-grade only. As of mid-2026, 5-amino-1MQ is not FDA-approved for any use, is not a dietary supplement, and is not on the FDA 503A compounding list. It is sold as a “research chemical” or grey-market capsule; any use in a clinic is off-label and not backed by trials.
• Clinical trials: No registered or completed human trial of 5-amino-1MQ could be confirmed in any registry. Claims of “registered Phase 1 trials in some geographies” come with no verifiable registry ID and should be treated as unconfirmed.
• Anti-doping (WADA): It is not specifically named on the WADA 2026 Prohibited List (in effect since 1 January 2026), and there is no confirmable WADA classification or Monitoring-Program listing for it. It is not a GLP-1 agonist (blocking NNMT works a completely different way), and it is not a growth factor. For context, the 2026 List puts GLP-1 agonists such as semaglutide and tirzepatide on the Monitoring Program — not prohibited (an online claim that they were “moved to S4 prohibition” is not supported by the primary WADA documents). For athletes, an unlisted experimental metabolic drug can still cause problems under broad catch-all rules, and as a grey-market product it is prone to contamination — so clear anything with your anti-doping authority first. The exact WADA category is unsettled, not confirmed.

Safety

• No human safety data exist. Safety rests entirely on rodent studies, where the doses tested were reportedly tolerated reasonably well — no reported deaths or obvious organ damage in the published mouse work, and the 2024 metabolic-disease paper reported better liver readings and less fat in the liver in treated obese mice.
• Anecdotal human “side effects” are not evidence. Marketing and clinic reports of mild stomach upset or anecdotal shifts in thyroid markers are uncontrolled, have no baseline measurements, and cannot prove cause and effect. That is anecdote, not data.
• Real unknowns: what happens over the long term if you keep altering the body’s NAD+ and methyl-donor (SAM) balance; off-target effects (this chemical family has documented limits on selectivity and on how long it lasts before breaking down); and the quality and purity risks that come with any grey-market “research chemical.” Bottom line: it is unapproved, and human safety has not been established.

Bottom line

5-Amino-1MQ is a small molecule that blocks NNMT — not a peptide — with a genuinely interesting mechanism and encouraging mouse data across obesity, metabolic disease, and muscle aging. But the gap between that and the marketing is wide: there is no verifiable human trial, no approval, no confirmable trial registration, and no human safety data. The “muscle-sparing fat loss” pitch is partly stretched from aged-mouse muscle studies, not shown as preserved lean mass in the obesity work. It is a research-grade, grey-market chemical that is often, and wrongly, sold as a peptide.

A sourcing caution: many consumer pages mislabel this as a “peptide,” and some cite a fabricated PubMed ID (29183836) for the founding study — that PMID actually points to an unrelated 2018 vinpocetine review (Zhang et al., Eur J Pharmacol) and should be ignored. The correct PMID for the founding study is 29155147. Check any citation before you rely on it.

Evidence grade: 3/10 · Animal only.

Sources

• Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of NNMT reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141-152. PMID 29155147
• Babula JJ, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024;26(11):5272-5282. PMID 39161060
• Dimet-Wiley A, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports. 2022. PMID 35013352
• Dimet-Wiley AL, et al. NNMT inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Scientific Reports. 2024. PMC11226645
• Kannt A, et al. A small molecule inhibitor of NNMT for the treatment of metabolic disorders (JBSNF-000088 — different compound, class context). Scientific Reports. 2018. PMID 29483571
• Iyamu ID, Huang R. Mechanisms and inhibitors of nicotinamide N-methyltransferase. RSC Med Chem. 2021;12(8):1254-1261. PMC8372200
• WADA 2026 Prohibited List (in force 1 Jan 2026; 5-amino-1MQ not specifically named; GLP-1s on Monitoring Program)